about
Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathwayIdentification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA)Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma modelAcquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5.PTEN action in leukaemia dictated by the tissue microenvironment.Cks1 is required for tumor cell proliferation but not sufficient to induce hematopoietic malignanciesA tumour suppressor network relying on the polyamine-hypusine axis.A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.A rapid and scalable system for studying gene function in mice using conditional RNA interference.Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatmentNF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta.Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment options.A pipeline for the generation of shRNA transgenic miceImatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).Analysing c-kit internalization using a functional c-kit-EGFP chimera containing the fluorochrome within the extracellular domain.The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
P50
Q28215538-6921AE30-AC17-4AA2-8B55-57721692D298Q28588852-0BE28772-167D-4E40-A2B9-45569610D829Q33693027-25D5BB1E-8AA7-4828-8268-6002A7092D02Q33907381-6D10B7CD-163E-47B5-959C-58CFB7B4A50EQ34196262-AFCC15B8-7DC3-4745-B552-2DE1CDB2E7ECQ34279980-38CA9F72-C419-46A8-8183-B01DBD595E4AQ34313461-75F26784-BA34-4F32-B579-9B02FAEF4B38Q34369388-AC1326F9-AEDA-4D5C-9A0D-C53CB8B4ED0BQ35627849-7C0A78B1-A381-4766-981F-4D9A3E4F7FEDQ35663526-B2BA1C1E-1A18-4C88-A226-FC771EF8C072Q36259805-7E2F6060-E0F5-4ABC-9D7D-7C83F49FBD5EQ36638465-0F4AF369-7BDC-4592-A452-3529158DD8CFQ37047996-21681EBC-6205-452A-BE99-56CC6E2C8D21Q39947042-F761E0E9-175A-4A91-AC44-E0CFFAB39FF1Q40278066-963C5D46-DC8B-458D-8EB1-97B569EC2BD6Q40562858-24FF0C61-1B29-4106-AFF7-0D75CED4EBF6Q40647447-0D93C74E-3099-405E-A31A-FF09EDEEAC97Q40722134-B593B9E9-6402-40EC-B617-282DC2DF7A22Q44524417-3E691866-3A45-4471-BF1F-9A9C57B6DD0BQ45271875-D1DF9D4A-7464-4894-9DA2-B4BDA68671D5
P50
name
Cornelius Miething
@ast
Cornelius Miething
@en
Cornelius Miething
@es
Cornelius Miething
@fr
Cornelius Miething
@nl
type
label
Cornelius Miething
@ast
Cornelius Miething
@en
Cornelius Miething
@es
Cornelius Miething
@fr
Cornelius Miething
@nl
prefLabel
Cornelius Miething
@ast
Cornelius Miething
@en
Cornelius Miething
@es
Cornelius Miething
@fr
Cornelius Miething
@nl